Regenerative Medical Technology Group Inc. (RMTG)
Oxford Ledge is still expanding full research coverage of RMTG. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
RMTG operates an integrated regenerative medicine platform combining physician education, product manufacturing, and clinical delivery globally.
Source: 10-K (2025-12-31) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- 10-Q Quarterly financial report (unaudited) 2026-06-09
- 10-K Annual financial report with audited statements 2026-05-14
- 10-Q Quarterly financial report (unaudited) 2025-11-19
- 10-Q Quarterly financial report (unaudited) 2025-08-19
- 8-K Results of operations / financial condition; Financial statements and exhibits 2025-05-21
Source: SEC EDGAR.
Annual results
5 years of annual figures for RMTG, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | $5.1M | -$7.8M | -$0.62 |
| 2024 | $4.1M | -$5.6M | -$0.44 |
| 2023 | $2.4M | -$9.8M | -$0.79 |
| 2022 | $1.5M | -$5.5M | -$0.45 |
| 2021 | $437,887 | -$12.9M | -$1.12 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
1 recent insider (SEC Form 4) filing on record for RMTG. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open RMTG in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.